Skip to main content

Revision of Pembrolizumab Indication for Gastric Cancer

The FDA has amended the existing indication of pembrolizumab (Keytruda®, Merck) with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. While this indication remains approved under the accelerated approval regulations, this revision restricts its use to patients whose tumors e...

Continue reading

Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma with Kohei Shitara, MD

In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.  

Continue reading